Catalog

CC-20

Version 1.0

A Stepwise Approach to Acid-Base Results

Apply a six-step worksheet to acid-base results, assess compensation, and recognize when specimen, method, or mixed-process uncertainty prevents a simple label.

CC-03

Version 1.0

Accuracy, Precision, Bias, and Measurement Uncertainty

A working method for describing why repeated results differ: separate imprecision (spread) from bias (closeness to a target), calculate mean, SD, and %CV, compare a result against an allowable-difference criterion, and state what a measurement uncertainty estimate does and does not claim.

CC-07

Version 1.0

Adrenal and Pituitary Laboratory Assessment

Cortisol, ACTH, prolactin, and growth hormone/IGF-1 results require timing and context. Interpret cortisol against its circadian pattern; pair ACTH with same-draw cortisol and its own preanalytical path; distinguish the questions posed by stimulation and suppression testing; and account for medication, illness, and assay factors that can turn a technically valid result into a misleading one.

CC-19

Version 1.0

Blood Gas Fundamentals

Learn which arterial blood gas values an analyzer directly measures with dedicated electrodes, which values it calculates, how co-oximetry works as a separate measurement, and how specimen type and handling defects change results before they ever reach the electrode.

CC-12

Version 1.0

Calcium, Phosphate, PTH, and Vitamin D

Integrate total calcium, albumin, ionized calcium, phosphate, magnesium, parathyroid hormone (PTH), and vitamin D markers into one interpretable pattern, and recognize when a total or corrected calcium result may not reflect the physiologically active fraction.

CC-02

Version 1.0

Calibration and Analytical Measurement Systems

How a laboratory establishes and verifies the relationship between instrument signal and assigned analyte value, why calibration, calibration verification, and quality control are three distinct activities, and what a technologist does when a calibration signal drifts.

CC-18

Version 1.0

Connecting Renal Chemistry with Urinalysis

Integrate eGFR, urine albumin and protein ratios, dipstick chemistry, sediment cells, and casts into a bounded kidney-injury pattern while recognizing discordance requiring repeat, confirmation, or local-policy escalation.

CC-17

Version 1.0

Creatinine, Cystatin C, and Estimated GFR

Creatinine and cystatin C are filtration markers, not direct measurements of glomerular filtration rate. Each marker is generated and handled by the kidney differently, the current race-free CKD-EPI equations require specific inputs, and a single eGFR is likely to mislead during acute kidney change, extremes of muscle mass, diet, pregnancy, in children, and during transplant evaluation. A paired creatinine-only and creatinine-cystatin C calculation walks through to a bench decision.

CC-26

Version 1.0

Drug Metabolism and Toxicology Methods

Interpret toxicology findings by connecting specimen selection, metabolism, screening design, confirmation, and the purpose of the cutoff.

CC-08

Version 1.0

Estradiol and the Hypothalamic-Pituitary-Gonadal Axis

Interpret a serum estradiol result against the hypothalamic-pituitary-gonadal (HPG) feedback loop, cycle phase, life stage, sex, and medication context, and recognize where immunoassay measurement runs out of low-end reliability.

CC-30

Version 1.0

Heavy Metals, Trace Elements, and Selected Toxins

Select contamination-controlled specimens and interpret trace-element results by matrix, timing, species, and analytical method.

CC-01

Version 1.1

How an Analyzer Produces a Result

Trace a chemistry result from specimen aspiration through signal generation, calculation, flags, and verified release, and learn where an otherwise plausible number can become unreliable before it ever fails a QC rule.

CC-16

Version 1.0

How Lipid-Lowering Therapy Changes Laboratory Results

Common lipid-lowering drug classes change lipid panel and safety-monitoring results in identifiable patterns. Separating an expected treatment response from nonadherence, biological variation, and analytical or method problems lets a delayed or internally inconsistent lipid trend get verified before it is read as a treatment effect.

CC-13

Version 1.0

Laboratory Assessment of Bone Health and Osteoporosis

How mineral homeostasis testing and bone-turnover markers support, but never replace, the DXA-based diagnosis of osteoporosis, with a guided case on collection timing and serial comparability.

CC-09

Version 1.0

Laboratory Diagnosis of Diabetes

Work through which laboratory findings can establish diabetes or increased glycemic risk in a nonpregnant adult, when a single abnormal result is enough versus when confirmation is required, and which specimen, hemoglobin, and assay conditions can make a criterion unreliable.

CC-11

Version 1.0

Metabolic Syndrome and Continuous Glucose Monitoring

Place fasting glucose, lipids, and CGM-derived metrics into a metabolic-risk picture, learn which criteria version and glucose threshold a metabolic-syndrome classification depends on, and interpret an ambulatory glucose profile with attention to sensor data sufficiency and the difference between GMI and laboratory A1c.

CC-10

Version 1.0

Monitoring Diabetes: Glucose, A1c, and Their Limitations

A working guide to reconciling spot glucose, serial or self-monitored glucose, A1c, fructosamine/glycated albumin, and CGM summaries when they describe the same patient differently. Covers the time window each measure represents, the biological and analytical causes of A1c-glucose mismatch, and how to frame a bounded laboratory communication when the numbers disagree.

CC-21

Version 1.0

Oxygen Transport and the Oxyhemoglobin Dissociation Curve

Interpret oxygen tension, saturation, hemoglobin fractions, and arterial oxygen content as related but distinct laboratory information.

CC-29

Version 1.0

Pharmacogenomics for the Laboratory Professional

Follow a pharmacogenomic result from a detected variant through diplotype and predicted phenotype to a bounded, current report.

CC-31

Version 1.0

Preeclampsia Testing and Emerging Biomarkers

Use routine laboratory evidence and a bounded, assay-specific angiogenic biomarker result to support evaluation of suspected preeclampsia without turning a risk assay into a diagnosis.

CC-22

Version 1.0

Protein Electrophoresis and Pattern Recognition

Recognize serum and urine protein electrophoresis patterns, identify look-alikes, and select bounded laboratory follow-up.

CC-15

Version 1.0

Reading a Lipid Panel

Interpret a standard lipid panel by separating what the analyzer measures from what is calculated, verify the calculation behind LDL-C and non-HDL-C, and recognize when triglycerides are too high for a calculated LDL-C result to be reported.

CC-05

Version 1.0

Reading an Endocrine Feedback Loop

A stimulating hormone and its target-gland hormone travel together as a pair, not as two independent numbers. The negative-feedback model behind that pair shows how the direction of both values localizes a problem to the target gland versus the pituitary or hypothalamus; timing, binding-protein, illness, and assay-interference factors can make that pattern mislead a reader who has not checked the context behind the numbers.

CC-04

Version 1.0

Sensitivity, Specificity, and Specimen Interference

A method's ability to detect a measurand and a test's ability to diagnose a condition are two different questions, and a flagged or unflagged specimen does not settle either one by itself. Limit of blank, limit of detection, and limit of quantitation differ from diagnostic sensitivity, specificity, and predictive value. Hemolysis, biotin, and heterophile antibody interference can require a defensible next step for a discordant result.

CC-24

Version 1.0

Sepsis Biomarkers: Uses and Limitations

Use lactate, procalcitonin, CRP, culture timing, and evidence labels as time-dependent adjuncts without turning any single result into a sepsis diagnosis.

CC-14

Version 1.0

Serial Cardiac Biomarkers and Myocardial Injury

Work through how to read serial high-sensitivity cardiac troponin (hs-cTn) results: what the assay-specific 99th-percentile upper reference limit (URL) means, how a rise or fall pattern distinguishes acute from chronic myocardial injury, how the ESC 0h/1h sampling algorithm classifies a patient into rule-out, observe, or rule-in zones, and how to recognize nonischemic causes and analytical interferents such as macrotroponin before a discordant result is escalated.

CC-23

Version 1.0

The Laboratory Role in Cystic Fibrosis Testing

Use newborn-screening, sweat chloride, and CFTR molecular results as distinct evidence streams while protecting sweat specimen adequacy and reporting uncertainty clearly.

CC-27

Version 1.0

Therapeutic Drug Monitoring

Evaluate whether a therapeutic drug concentration was collected at the right time and can answer the monitoring question.

CC-06

Version 1.0

Thyroid Testing as a Pattern

A TSH result comes back suppressed with no free T4 measured yet. The pattern-recognition framework for TSH, free T4, total T4/T3, and thyroid antibody results covers classifying primary versus central hypo- and hyperthyroid directions, recognizing when total and free hormone can legitimately disagree, and knowing when biotin, heterophile antibodies, macro-TSH, or nonthyroidal illness should stop a diagnostic statement rather than support one.

CC-25

Version 1.0

Tumor Markers: What They Can and Cannot Tell You

Use tumor-marker results by purpose, serial pattern, and method context. Recognize why an abnormal result supports a clinical question but rarely establishes cancer.

CC-28

Version 1.0

Urine Drug and Opiate Testing

Interpret urine drug-testing patterns by assay target, metabolites, specimen validity, cutoff, and confirmation status.

COAG-07

Version 1.0

Acquired Coagulopathy, Consumption, and Thrombotic Patterns

A working framework for reading deteriorating platelet count, PT, aPTT, fibrinogen, and D-dimer together over time, separating an evolving consumption pattern from liver-related, dilutional, vitamin K-related, and thrombotic microangiopathy look-alikes, and deciding what needs urgent communication.

COAG-03

Version 1.0

Anticoagulants and Their Effects on Laboratory Tests

Anticoagulant drug classes act on different points in the clotting cascade, so PT, aPTT, thrombin time, and anti-Xa assays respond differently depending on which drug is present, which method is used, and which reagent is on the analyzer. Vitamin K antagonists, unfractionated and low-molecular-weight heparin, direct thrombin inhibitors, and factor Xa inhibitors map to the tests they affect, the dedicated assays used to measure them, and the specimen and reagent pitfalls that can mimic or mask an anticoagulant effect.

COAG-04

Version 1.0

Antiplatelet Drugs and Laboratory Monitoring

A working guide to matching aspirin, P2Y12 inhibitors, GP IIb/IIIa inhibitors, and phosphodiesterase III inhibitors to the platelet pathway each one alters, choosing the test family that actually answers a defined pharmacodynamic question, and recognizing the preanalytical and biological factors that can be mistaken for drug effect.

COAG-11

Version 1.0

Coagulation Cases: Putting the Entire Pattern Together

A capstone set of coagulation cases that requires the same reasoning sequence learned across prior coagulation modules: check the specimen and medication history first, build a ranked laboratory differential from the screening pattern, and choose the next test that most separates the leading explanations while preserving uncertainty.

COAG-09

Version 1.0

Distinguishing Factor Deficiency from Inhibition

After a mixing study flags a possible inhibitor, work through choosing factor assays and inhibitor studies, reading one-stage and chromogenic FVIII results together, and recognizing lupus anticoagulant, heparin, and DOAC interference before an inhibitor titer is trusted.

COAG-10

Version 1.0

Lupus Anticoagulant Evaluation as a Laboratory Workflow

Work through the screen, mix, and confirm logic that a coagulation laboratory uses to evaluate lupus anticoagulant across two complementary assay principles, dRVVT and a silica-based aPTT system, and choose a defensible report category with the correct limitation language.

COAG-08

Version 1.0

Mixing Studies Step by Step

A stepwise walk through the screening 1:1 patient-to-normal-pooled-plasma mixing study: when it is indicated, how to prepare and time it, how to read immediate versus incubated aPTT results, how to calculate a local index, and how to route the classified pattern to the right follow-up test.

COAG-05

Version 1.0

Platelet-Function Testing: Methods, Results, and Limitations

Compares light-transmission aggregometry, whole-blood impedance, high-shear closure time, lumiaggregometry, and flow cytometry as platelet-function methods, and works one PFA case through specimen validation, pattern recognition, and the boundary between a compatible pattern and a diagnosis.

COAG-01

Version 1.0

Primary Hemostasis: Vessels, Platelets, and the Initial Plug

Follow the initial platelet plug from vascular injury through aggregation, then use count, smear, and aggregometry observations to localize a quantitative, adhesion, or aggregation problem.

COAG-06

Version 1.0

Recognizing Common Bleeding-Disorder Patterns

Use platelet count, PT, aPTT, fibrinogen, and a focused bleeding history together to sort an initial bleeding differential into isolated platelet, isolated PT, isolated aPTT, combined, and normal-screen patterns, then choose a targeted next test without diagnosing from the screen alone.

COAG-02

Version 1.0

Secondary Hemostasis and the Meaning of Screening Tests

A working tour of the cell-based model of coagulation paired with what PT, aPTT, thrombin time, fibrinogen, and anti-Xa actually challenge in vitro, built around a guided case with an isolated prolonged aPTT.

GLP-06

Version 1.0

Accept, Reject, or Investigate?

A practical walk through the risk-based decision a laboratory professional makes when a specimen arrives imperfect: reject it, request recollection, correct a processing defect, or accept it under a documented, approved exception. Builds a repeatable risk screen, a defect-to-disposition matrix, and a guided case using a hemolysis index, then asks the learner to disposition five case cards and identify which one also needs nonconforming-event review.

GLP-09

Version 1.0

Accuracy, Precision, Mean, SD, and CV

A working guide to the descriptive statistics a bench technologist uses to read control performance: mean, sample standard deviation, coefficient of variation, bias, and standardized distance, with a worked five-result run and a ten-day drift dataset that shows why a plot and a defined dataset come before any calculation.

GLP-11

Version 1.0

Applying Laboratory Control Rules

A morning QC run flags two control results beyond 2 SD on the same side. Reading a control-rule pattern, telling warning from rejection, matching the pattern to random or systematic error, and sequencing the corrective action ensure patient results are actually reviewed instead of quietly repeated away.

GLP-24

Version 1.0

Biosafety Cabinets, Fume Hoods, and Infectious Materials

Match a containment device to its hazard, work in a Class II biosafety cabinet without disrupting containment, and respond to a suspected aerosol release from a broken centrifuge cup.

GLP-35

Version 1.0

Budgeting, Inventory, and Operational Decisions

A guided walkthrough of how a laboratory forecasts test volume, sizes reagent orders, sets a reorder point and safety stock, prices a test with fixed and variable costs, compares owning an instrument to reagent rental, and makes a bounded, defensible decision during a reagent shortage.

GLP-13

Version 1.0

Building an Individualized Quality Control Plan

Work through how a laboratory builds an IQCP: a risk assessment across specimen, environment, reagent, test system, and personnel; a written quality control plan with layered controls; and an ongoing quality assessment process with a defined change trigger, using a reagent-lot failure to make the reasoning concrete.

GLP-17

Version 1.0

Calibration Verification, Acceptance Criteria, and Implementation

A hospital core lab changes its glucose reagent lot and must show the method still reports accurately across its reportable range before the new lot goes live. Select challenge materials, apply documented acceptance limits, read recovery and residuals, and convert a completed study into a go-live decision.

GLP-03

Version 1.0

Capillary Collection and Difficult Draws

Select and perform capillary collection appropriately, understand why capillary blood is not automatically interchangeable with venous blood, and adapt safely when a venous draw is difficult.

GLP-07

Version 1.0

Centrifuge Operation, Balance, and Safety

A working guide to relative centrifugal force, rotor selection, balanced loading, and safe response to centrifuge defects and spills, built around a serum-tube run.

GLP-20

Version 1.0

CLIA, Accreditors, and Laboratory Personnel Requirements

A working map of who governs U.S. clinical laboratory testing: CLIA statute and 42 CFR Part 493, CMS interpretive guidance, deemed accreditors such as CAP, state law, and local policy. Covers waived, moderate, and high-complexity test classification, the five CLIA certificate types, and the personnel qualification pathways for director, supervisor, and testing-personnel roles, with an emphasis on locating and verifying the current primary-source text rather than memorizing it.

GLP-32

Version 1.0

Communication, Staffing, and Team Coordination

A second-shift core laboratory scenario walks through the shift huddle, an SBAR critical-value call with closed-loop read-back, and a staffing shortage escalated through a skill matrix, so that workload, risk, and handoffs are not lost between people or shifts.

GLP-42

Version 1.0

Competency Assessment and Assessment Alignment

Design workplace competency assessments that collect defensible evidence of the specific knowledge, skill, and problem-solving performance required for assigned laboratory work.

GLP-26

Version 1.0

Compressed Gases, Cryogens, Dry Ice, and Liquid Nitrogen

Covers safe handling of compressed-gas cylinders and cryogens in the laboratory: cylinder inspection, securement, and segregation; liquid nitrogen (LN2) and dry ice hazards from extreme cold, expansion, and oxygen displacement; personal protective equipment for cryogen transfer; and emergency response to a low-oxygen alarm or a suspect sealed cryovial.

GLP-40

Version 1.0

Conducting a Laboratory Sustainability Audit

Conduct a bounded laboratory sustainability audit that identifies feasible reductions in energy, water, materials, and waste without compromising biosafety, analytical quality, or patient care.

GLP-28

Version 1.0

Emergency Readiness, First Aid, Disaster, and Active-Threat Planning

An all-hazards framework for the first minutes of a laboratory exposure, spill, outage, disaster, or security threat: protect people, give correct immediate first aid, evacuate or shelter as directed, account for staff, and hand off to incident command while continuity and after-action steps follow.

GLP-36

Version 1.0

Excel Analysis and Laboratory Data Visualization

A guided walkthrough of building a validated, auditable spreadsheet analysis from a raw laboratory export: cleaning data without altering the source, writing structured formulas that are tested and locked, and choosing an honest chart for the question being asked.

GLP-27

Version 1.0

Fire, Electrical, Sharps, Ergonomic, and Fall Hazards

A working framework for the ordinary physical hazards on a general laboratory bench: fire, electrical, sharps, ergonomic, and slip/trip/fall risk, plus heat and mechanical pinch points. Covers recognition, hierarchy-of-controls prevention, and the bounded immediate response and reporting steps a bench technologist can take before handing off to authorized personnel.

GLP-01

Version 1.1

Following a Result through the Total Testing Process

A result can fail before an analyzer ever sees the specimen, and it can fail after the analyzer prints a number. Trace a basic metabolic panel from order to clinical use, name the owner and record at each handoff, and work one guided case where a hemolyzed, high-potassium specimen is the earliest failed control rather than the analyzer.

GLP-39

Version 1.0

Harassment, Discrimination, and Professional Workplace Conduct

Recognize workplace-conduct concerns, preserve objective facts, and use appropriate safety, reporting, accommodation, and nonretaliation pathways in the laboratory.

GLP-25

Version 1.0

Hazard Communication, SDS Use, Formaldehyde, and Waste

Read a GHS label and locate the right SDS section fast, tell acute from chronic and physical hazards apart, segregate incompatible chemicals correctly, and decide when a formaldehyde or chemical spill is incidental cleanup versus an emergency response requiring evacuation.

GLP-21

Version 1.0

Inspection Readiness, Common Deficiencies, and Competency

How a CLIA survey or CAP inspection actually samples the operating quality system, what the six required CLIA competency-assessment procedures cover and how often they run, and how to trace evidence and draft a systemic deficiency response when a record is missing.

GLP-38

Version 1.0

Laboratory Ethics, Privacy, and Healthcare Compliance

A module on laboratory ethics, privacy, and healthcare compliance for medical laboratory professionals. Learners work through a pressured, after-hours specimen result to practice a five-question ethics frame, HIPAA minimum necessary and security principles, and the laboratory chain of command, then examine correcting records, proficiency testing integrity, billing and coding fraud risk, and retaliation protections under federal law and professional codes.

GLP-34

Version 1.0

Laboratory Utilization, Vendors, and Instrument Selection

Build a defensible instrument or vendor decision using a needs assessment, a transparent weighted scorecard, a total-cost-of-ownership calculation, and a vendor claim audit, then design a utilization intervention that reduces low-value testing without blocking legitimate exceptions.

GLP-15

Version 1.0

Lot-to-Lot Verification and Corrective Action

A candidate reagent, calibrator, or control lot can pass quality control and still shift patient results. Plan a patient-sample lot comparison, read a difference plot against medical decision points, and run a bounded corrective-action decision when a lot looks different enough to matter.

GLP-18

Version 1.0

Managing a Nonconforming Laboratory Event

A workflow for recognizing, containing, documenting, and closing a nonconforming laboratory event, built around a potassium quality-control failure that reached patient results, with the boundary between immediate correction and systemic corrective action kept explicit throughout.

GLP-04

Version 1.0

Order of Draw, Communication, and Special Collections

Work through the current venous order of draw, why additive carryover (not cap color) drives it, and how timing, chilling, light protection, and closed-loop communication keep a specimen defensible from needle to bench.

GLP-08

Version 1.0

Pipette Technique, Verification, and Maintenance

Manual pipetting technique creates systematic or random volume error; a laboratory verifies pipette performance with gravimetric data. You will select an air-displacement or positive-displacement pipette for a given liquid, follow the technique variables that most affect delivery, calculate bias and imprecision from a gravimetric data set, and diagnose a replicate error pattern using supplied criteria.

GLP-16

Version 1.0

Planning a Validation or Verification Study

Before a new or modified method touches a patient specimen, the laboratory has to know which studies it owes: a short verification of an unmodified FDA-cleared method, or a full validation of a modified or laboratory-developed one. Classify the method, match each performance characteristic to its pathway, work an EP15-style precision and bias verification, and close the readiness gate before go-live.

GLP-31

Version 1.0

POCT Competency and Continuous Glucose Monitoring

Build the competency and quality controls that keep bedside glucose and continuous glucose monitoring (CGM) results safe to act on: who is authorized to test, what makes a bedside glucose result unreliable, how CGM data reaches the chart, and when a result needs central-lab confirmation before a dose decision is made.

GLP-30

Version 1.0

POCT Oversight, Compliance, and Quality

Point-of-care testing (POCT) puts laboratory-quality results in the hands of staff who are not laboratorians, on devices scattered across a facility. A governance model keeps that testing under one quality system: who owns test selection and validation, how operators are authorized and monitored, what quality indicators reveal about a decentralized program, and how the laboratory contains a system-wide device problem instead of chasing it site by site.

GLP-14

Version 1.0

Proficiency Testing and Alternate Assessment

A routine chemistry bench walks through one proficiency testing (PT) event, from enrollment through an unacceptable sodium result, then covers when alternate assessment substitutes for PT and how to investigate and document unacceptable performance without treating it as random error.

GLP-10

Version 1.0

Reading a Levey-Jennings Chart

Learn to read a Levey-Jennings quality-control chart: plot control results against the target mean and SD limits, recognize isolated extremes, shifts, trends, increased scatter, and cyclical patterns, and connect the timing of a pattern to reagent, calibration, maintenance, environment, or operator events without treating the chart alone as a cause.

GLP-12

Version 1.0

Regression and Practical Laboratory Math

Work the calculations that come up every shift, dilutions, recoveries, and percent bias, then read a method-comparison scatter plot without mistaking a strong correlation for proven agreement.

GLP-19

Version 1.0

Root Cause, CAPA, Risk, and Continuous Improvement

A framework for investigating a laboratory nonconforming event, distinguishing a correction from a corrective action, choosing higher-leverage controls over training alone, and defining a measurable effectiveness check, worked through a hemolyzed-potassium release.

GLP-02

Version 1.0

Safe Venipuncture and Positive Patient Identification

A practical walk through positive patient identification, safe venous collection technique, and immediate labeling, built around an identity discrepancy and a routine two-tube draw.

GLP-29

Version 1.0

Selecting, Packaging, Labeling, and Documenting Infectious-Material Shipments

Classify a specimen or culture for transport as exempt, Category B, Category A, or regulated medical waste, then assemble the triple packaging, marks, labels, and documentation the classification requires under current DOT/PHMSA and IATA rules.

GLP-23

Version 1.0

Standard Precautions, PPE, and Exposure Prevention

Standard precautions treat every specimen as potentially infectious. The hierarchy-of-controls habit: identify the exposure route first, choose engineering and work-practice controls before reaching for personal protective equipment, and don and doff PPE without contaminating yourself. A guided bench case and an exposure scenario put the reasoning to work.

GLP-05

Version 1.0

Transport, Temperature, Time, and Stability

A specimen changes between collection and analysis. A delayed, warm, or light-exposed specimen can be biased even when its container and identity are intact; separate biological stability from physical integrity and identification security, and walk an emergency-department specimen set through a transport excursion so you can document it and choose a defensible next step.

GLP-37

Version 1.0

Using Large Language Models Safely in Laboratory Workflows

A working guide to using approved generative-AI tools for low-risk laboratory tasks: how to classify a use case by risk, what may and may not go into a prompt, how to catch a fabricated citation or number before it reaches a colleague, and how to build a defensible human-review and audit trail.

GLP-33

Version 1.0

Workflow, Productivity, Lean, and Six Sigma

Map laboratory workflow with value-stream and turnaround-time data, tell value apart from waste and necessary non-value work using Lean's eight wastes, and select and test one small improvement with PDSA or DMAIC while tracking balancing measures so a change is proven safe before it becomes policy.

GLP-22

Version 1.0

Writing and Maintaining Controlled Laboratory Documents

A controlled document tells the right person exactly what to do while staying approved, current, traceable, and usable. Covers the document hierarchy, the required content of a procedure, the lifecycle from need through retirement, and how a form becomes a record once it is filled in.

GLP-41

Version 1.0

Writing Objectives and Building an Instructional Unit

Repair a misaligned point-of-care glucose meter training plan by defining one observable capability, writing measurable objectives, and sequencing evidence, instruction, practice, and feedback.

HEME-10

Version 1.0

Aggregation and Distortion: Rouleaux, Agglutination, and Artifacts

Use smear distribution and CBC plausibility to distinguish rouleaux, cold-reactive agglutination, and preparation artifacts, then choose only validated corrective actions.

HEME-17

Version 1.0

Alpha- and Beta-Thalassemia Patterns

Use CBC indices, smear findings, hemoglobin fractions, age, iron status, and bounded follow-up to recognize thalassemia patterns without assigning genotype from one result.

HEME-12

Version 1.0

Anemia as an Index-Driven Problem

Organize anemia with hemoglobin, MCV, RDW, reticulocyte response, and peripheral smear findings before selecting focused follow-up.

HEME-02

Version 1.0

Bone Marrow Collection and Basic Morphologic Review

Evaluate marrow aspirate and core-related specimen quality, allocate material deliberately, and complete an introductory, preparation-aware morphologic review without issuing a diagnosis.

HEME-21

Version 1.0

Chromatin, Cytoplasmic Inclusions, and Findings That Require Escalation

Use observable leukocyte morphology, CBC correlation, and local policy to describe high-concern findings without forcing an image-only diagnosis.

HEME-25

Version 1.0

Chronic Myeloid Leukemia: Pattern, Confirmation, and Molecular Monitoring

Recognize a CML-supportive blood pattern, select bounded BCR::ABL1 confirmation, and protect molecular trend interpretation from method-related error.

HEME-22

Version 1.0

Flagged Neutrophilia: A Bounded CBC and Smear Workflow

Use one locally governed workflow to verify a flagged neutrophilia result, calculate and compare the local ANC, resolve the immature-granulocyte flag on a Wright-Giemsa smear, and route rather than diagnose.

HEME-28

Version 1.0

Flow Cytometry Fundamentals and Gating

Learn how a flow cytometer records single-cell events and how a reproducible gate hierarchy, controls, and stated denominator support a bounded hematology result.

HEME-01

Version 1.0

Hematopoietic Lineages from Stem Cell to Peripheral Blood

Use a practical lineage map and visible maturation features to orient cells from marrow production to the peripheral blood film.

HEME-32

Version 1.0

Hematopoietic Stem-Cell Transplantation: A Laboratory Timeline

Follow the laboratory questions that arise before collection, during conditioning and infusion, through engraftment, and during post-transplant monitoring after hematopoietic stem-cell transplantation (HSCT), connecting collection, product testing, engraftment, chimerism, disease monitoring, transfusion support, and complication workups within stated method limits.

HEME-18

Version 1.0

Hemoglobin S Disorders and Common Analytical Patterns

Interpret HbS-containing patterns with fraction accounting, paired methods, morphology, age, and transfusion history while keeping genotype confirmation bounded.

HEME-15

Version 1.0

Hemolytic and Other Nonneoplastic Red-Cell Disorders

Use an integrated laboratory pattern to recognize increased red-cell destruction, separate it from specimen hemolysis, and choose bounded follow-up.

HEME-06

Version 1.0

Histograms, Scattergrams, and Analyzer Flags

Use declared Sysmex XN-series WDF/WNR and impedance evidence with CBC results, specimen inspection, and labeled smear review to make a validated local laboratory decision.

HEME-16

Version 1.0

How Hemoglobin Analysis Methods Work

Compare the evidence produced by major hemoglobin analysis methods, recognize method limits, and select a bounded confirmatory action.

HEME-29

Version 1.0

Introductory Immature B-Lineage Flow Case

Use declared sequential gates, an immature B-cell comparator, and bounded correlation to describe one immature B-lineage population without assigning a final disease entity.

HEME-19

Version 1.0

Iron Studies and Hereditary Hemochromatosis

Interpret serum iron, transferrin saturation, ferritin, inflammatory context, liver injury, and targeted HFE testing without treating a single result as proof of iron overload.

HEME-14

Version 1.0

Macrocytic Anemia Patterns

Organize macrocytosis with the CBC, peripheral smear, reticulocytes, nutrient markers, chemistry, and escalation findings without turning a pattern into a diagnosis.

HEME-09

Version 1.0

Membrane, Fragmentation, and Oxidative Red-Cell Morphology

Identify selected red-cell forms from visible features, standardize a schistocyte estimate, and choose a bounded review action.

HEME-13

Version 1.0

Microcytic Anemia Patterns

Use CBC indices, peripheral-smear findings, iron studies, and inflammation context to separate common microcytic-pattern families and choose a bounded next laboratory action.

HEME-26

Version 1.0

Myelodysplastic Neoplasms: Building an Integrated Workup

Recognize concerning cytopenia and dysplasia patterns, exclude common mimics, and select the marrow and ancillary evidence needed for integrated MDS classification.

HEME-27

Version 1.0

Myeloproliferative Neoplasms: Integrated Pattern Evaluation

Recognize sustained count and morphologic patterns that support a bounded MPN workup, then integrate molecular and marrow evidence without overcalling an entity.

HEME-03

Version 1.0

Normal Red Cells and Platelets

Establish a defensible visual baseline for normal red-cell and platelet backgrounds before naming abnormalities.

HEME-04

Version 1.0

Normal White Cells and the Differential

Identify normal leukocytes, count a representative manual differential, and reconcile it with an automated result using a flagged specimen.

HEME-30

Version 1.0

Pediatric Anemia and Lead-Related Findings

Apply age-specific laboratory context to pediatric anemia patterns and handle blood-lead screening results without overstating what the result establishes.

HEME-31

Version 1.0

Pediatric Leukemia and Hemoglobinopathy Cases

Interpret pediatric leukemia and hemoglobinopathy cases by integrating age-specific CBC and smear evidence, flow context, newborn hemoglobin patterns, transfusion history, specimen stewardship, and urgent communication boundaries.

HEME-20

Version 1.0

Reactive Granulocyte Changes

Classify common reactive neutrophil changes with the CBC differential, specimen age, film quality, and local review policy.

HEME-05

Version 1.0

Reading the CBC through Its Indices

Read measured and calculated complete blood count parameters as related evidence, then choose a bounded review action.

HEME-24

Version 1.0

Recognizing Acute Leukemia Patterns

Recognize CBC, analyzer, and peripheral-smear patterns concerning for acute leukemia; protect material for ancillary studies; and communicate urgently without assigning a final subtype from morphology alone.

HEME-11

Version 1.0

Red-Cell Inclusions and What They Represent

Use morphology, stain selection, and bounded interpretation to distinguish common red-cell inclusions from look-alikes.

HEME-08

Version 1.0

Red-Cell Size, Color, and Distribution

Use the monolayer, CBC indices, histogram shape, and specimen context to describe red-cell size, hemoglobinization, and population distribution without assigning an unsupported cause.

HEME-23

Version 1.0

True versus Spurious Thrombocytopenia

Confirm whether a low platelet count is analytically reliable before it is released or used for urgent communication. Use specimen evidence, analyzer clues, smear distribution, and validated alternate methods to separate clumping and other analytical causes from true thrombocytopenia.

HEME-07

Version 1.0

When CBC Results Are Spurious

Use CBC internal consistency, specimen evidence, analyzer information, and validated verification methods to recognize and investigate spurious results before release.

UBF-04

Version 1.0

A Systematic Approach to Urine Sediment

A working method for scanning, identifying, quantifying, and reporting urine sediment so the result reflects the whole preparation, not just the most obvious field. Covers preparation and concentration factors, the fixed low-power to high-power scanning sequence, optical modes, automated particle analysis with manual confirmation, and documentation of specimen age and difficult identifications.

UBF-13

Version 1.0

Bronchoalveolar Lavage Cell Morphology

A working guide to reading bronchoalveolar lavage (BAL) cytospin differentials: how the specimen is collected and prepared, what a normal cell distribution looks like, how to judge whether a specimen is adequate to trust, how to read macrophage pigment and hemosiderin, and where the bench-level call stops and cytopathology or microbiology review begins.

UBF-05

Version 1.0

Cells, Organisms, and Common Artifacts in Urine Sediment

A practical guide to sorting red cells, white cells, epithelial cells, yeast, bacteria, sperm, motile organisms, and common artifacts on manual urine microscopy. Builds a size-first, feature-based approach using the red blood cell as an internal ruler, then applies it to a guided case and a classification decision.

UBF-10

Version 1.0

CSF Cell Identification and Pattern Interpretation

Work a cerebrospinal fluid (CSF) cytospin differential from specimen receipt through a reported pattern. Learn to recognize the common CSF leukocytes and artifacts, judge whether preservation and stain quality support identification, and correlate the differential with cell counts, protein, glucose, and pending microbiology so the laboratory flags what needs review without issuing an independent diagnosis.

UBF-09

Version 1.0

CSF Collection, Processing, and Cell Counts

A low-volume, time-sensitive cerebrospinal fluid (CSF) specimen must be allocated across chemistry, microbiology, and hematology, then examined promptly for a defensible manual cell count. An adult lumbar collection demonstrates receipt, allocation, Fuchs-Rosenthal chamber setup, duplicate-side counting, calculation, and the reporting limits for a traumatic or delayed specimen.

UBF-02

Version 1.0

Dipstick Testing: What Each Pad Is Actually Detecting

A urine reagent strip carries nine or ten independent reagent pads, each running its own chemistry with its own target, timing, and limits. The reaction principle behind each common pad separates direct detection from surrogate detection, and timing, lighting, storage, and specimen mixing are analytical controls rather than housekeeping. A guided panel shows how a reactive pad is correlated with microscopy before anything is escalated.

UBF-01

Version 1.0

From Collection to Analysis: Protecting the Urine Specimen

A urinalysis result is only as good as the specimen behind it. The path from collection purpose through labeling, transport, storage, and processing determines whether a urine specimen can be accepted, rejected, recollected, or released with qualification before its analytical findings are trusted.

UBF-07

Version 1.0

How Urinary Casts Form and How to Identify Them

A practical guide to why urinary casts are shaped like the tubules that make them and how to sort a true cast from mucus, a fiber, or a loose cell clump. Covers uromodulin-based matrix formation, the low-flow and concentration conditions that favor it, and the visual criteria (parallel sides, blunt ends, three-dimensional focus) that identify a cast before naming its category. Works through hyaline, granular, cellular, fatty, waxy, broad, and mixed casts using a guided case and paired look-alike comparisons.

UBF-11

Version 1.0

Pleural and Peritoneal Fluid Evaluation

A pleural fluid case walks through container selection, gross appearance, cell count and differential, and Light's criteria calculated against paired serum results, then draws the boundary between pleural and peritoneal frameworks and between validated and unvalidated body-fluid chemistry.

UBF-14

Version 1.0

Semen Analysis: From Collection to Result Interpretation

Work through a basic semen examination from collection history through microscopic classification. Confirm abstinence, collection completeness, and timing; calculate concentration and total sperm number from raw chamber counts; classify motility using current WHO terminology; and decide what a single result set can and cannot say about fertility.

UBF-12

Version 1.0

Synovial Fluid and Crystal Examination

Work a synovial fluid aspirate from collection through compensated polarized light crystal identification. Evaluate specimen suitability, run the cell count and differential, and use shape, birefringence sign, and orientation to separate monosodium urate and calcium pyrophosphate crystals from look-alikes, without letting a crystal finding cancel a concurrent infection workup.

UBF-06

Version 1.0

Urinary Crystals without Memorizing Every Shape

Work through how urine pH, morphology, polarization, solubility, and specimen handling narrow a crystal differential, then apply that reasoning to a guided fresh-versus-refrigerated case and a set of look-alikes that require timely review.

UBF-08

Version 1.0

Using Casts in Clinical Correlation

A cast forms inside a renal tubule, so a verified cast localizes material to the nephron before any diagnosis is possible. Hyaline, cellular, granular, waxy, and fatty casts are correlated with chemistry pad results, cell counts, and renal function to show how RBC casts, marked hematuria, high albuminuria, and reduced eGFR can cohere with an intrarenal bleeding pattern. The correlation process ranks interpretations, identifies the most useful confirmatory observation, and leads to a defensible next action under local escalation policy.

UBF-03

Version 1.0

When the Dipstick and the Patient Do Not Agree

A worked approach to urine results where chemical pads, sediment microscopy, and patient history point in different directions. Covers what each pad actually measures, the specimen and analytical variables that create a mismatch, and how to choose a repeat, alternate-method, or recollection step that the evidence actually supports.